potassium chloride0,3%+glucose5%/baxter (viaflo) 0,3%+5% sol.inf
baxter hellas ΕΠΕ - electrolytes with carbohydrates - ΔΙΑΛΥΜΑ ΓΙΑ ΕΓΧΥΣΗ - 0,3%+5% - ΔΙΑΛΥΜΑ ΕΝΕΣΙΜΟ ΜΕΓΑΛΟΥ ΟΓΚΟΥ ( >50 ml )
lidocaine hydrochloride/baxter 20mg/ml (w% w/w) inj.sol
baxter hellas ΕΠΕ - lidocaine - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 20mg/ml (w% w/w) - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
glucose 5%/baxter (viaflo) 5% w/v solution for infusion
baxter (hellas) epe (0000008332) 47, marinou antypa & anafis str, n. herakleio-attiki, 141 21 - glucose monohydrate - solution for infusion - 5% w/v - glucose monohydrate (0005996101) 5% w/v - glucose
ringer lactate/baxter(viaflo) solution for infusion
baxter (hellas) epe (0000008332) 47, marinou antypa & anafis str, n. herakleio-attiki, 141 21 - calcium chloride dihydrate; sodium lactate; potassium chloride; sodium chloride - solution for infusion - calcium chloride dihydrate (0010035048) 0,027% w/v; sodium lactate (0000072173) 0,32% w/v; potassium chloride (0007447407) 0,04% w/v; sodium chloride (0007647145) 0,6% w/v
sodium chloride + glucose/baxter (0.9+5)% w/v solution for infusion
baxter (hellas) epe (0000008332) 47, marinou antypa & anafis str, n. herakleio-attiki, 141 21 - glucose monohydrate; sodium chloride - solution for infusion - (0.9+5)% w/v - glucose monohydrate (0005996101) 5,5% w/v; sodium chloride (0007647145) 0,9% w/v - electrolytes with carbohydrates
sodium chloride/baxter(viaflo) 0.9% w/v solution for infusion
baxter (hellas) epe (0000008332) 47, marinou antypa & anafis str, n. herakleio-attiki, 141 21 - sodium chloride - solution for infusion - 0.9% w/v - sodium chloride (0007647145) 0,9% w/v - other i.v. solution additives
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - Αντινεοπλασματικοί παράγοντες - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
metronidazole/baxter (viaflo) 500mg/100ml inj.so.inf
baxter hellas ΕΠΕ - metronidazole - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ - 500mg/100ml
paracetamol/baxter 10mg/ml solution for infusion
baxter holding b.v. (0000011218) kobaltweg 49, utrecht, 3542 ce - paracetamol - solution for infusion - 10mg/ml - paracetamol (0000103902) 10mg
bupivacaine hydrochloride/baxter 0,25% inj.sol
baxter hellas ΕΠΕ - bupivacaine - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 0,25% - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ